Although single-cell DNA sequencing was not performed in these primary samples to confirm the coexistence of FLT3-ITD and RAS pathway mutations in the same AML cells, this data further support that TP-0903 is able to overcome drug resistance observed by gilteritinib when NRAS mutations are present. The gene discussed is FLT3; the disease is acute myeloid leukemia.